XERS logo

Xeris Biopharma Holdings (XERS) Company Overview

Profile

Full Name:

Xeris Biopharma Holdings, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 21, 2018

Indexes:

Not included

Website:

http://www.xerispharma.com

Description:

Xeris Biopharma Holdings develops innovative injectable medications using its unique formulation technology. The company focuses on creating easy-to-use treatments for chronic conditions, aiming to improve patient outcomes and enhance the delivery of medicines. Their products include solutions for diabetes and other serious health issues.

Key Details

Price

$4.17

Market Cap

$642.19 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$203.07 M(+23.89% YoY)

Annual EPS

-$0.37(+17.78% YoY)

PE Ratio

-

Annual ROE

185.16%

Annual Debt To Equity

-7.84

Beta

1.32

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Mar 6, 2025

Recent annual earnings:

Mar 6, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Mar 7, 25 Piper Sandler
Neutral
Mar 7, 25 HC Wainwright & Co.
Buy
Jan 29, 25 Jefferies
Buy
Nov 11, 24 Piper Sandler
Neutral
Nov 11, 24 HC Wainwright & Co.
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
May 31, 24 HC Wainwright & Co.
Buy
May 10, 24 Piper Sandler
Overweight
Mar 28, 24 Oppenheimer
Outperform
Mar 7, 24 HC Wainwright & Co.
Buy

Screeners with XERS included

Growing Shares Outstanding
US stocks
Stocks with high beta
Most recommended stocks
Best performing stocks last 3 months
Best performing stocks last 5 years
Stocks above SMA 50
Stocks below analysts price target
Stocks ready to break out
Healthcare sector

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$4.17
XERS price is $4.17

Price All-time High

$27.23
XERS price is currently -84.68% below its historical high of $27.23

Price Analysts Target

$6.00
XERS price is currently -30.47% lower than the consensus analysts' forecast

Price Most Recent Change

+2.75%
XERS price was up +2.75% on Mar 8, 2025

Price YTD Change

+23.42%
XERS price is up +23.42% since January 1st

Price 3-Year Change

+82.97%
XERS price is up +82.97% over the past 3 years

Market cap

Market Cap

$642.19 M
XERS market capitalization is $642.19 million

Market Cap 3-Year Change

+107.83%
XERS market capitalization is up +107.83% over the past 3 years

Market Cap All-time High

$642.19 M
XERS market capitalization is currently at an all-time high

Market Cap Sector Rank

70.53%
XERS market capitalization is higher than 70.53% of companies in Healthcare sector

Technical

Beta

1.32
XERS beta is 1.32

200-day SMA

$2.95
XERS price is currently +41.60% above its 200-day simple moving average

14-day RSI

70.54
XERS 14-day relative strength index is 70.54

30-day Relative Volume

2.77
XERS 30-day relative volume is 2.77

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$203.07 M
XERS annual revenue is $203.07 million

Annual Revenue Analysts Estimate

$260.39 M
XERS annual revenue is currently -22.01% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+23.89%
XERS annual revenue is up +23.89% year-on-year

Annual Revenue Sector Rank

64.21%
XERS annual revenue is higher than 64.21% of companies in Healthcare sector

Profit

Annual Gross Profit

$166.24 M
XERS annual gross profit is $166.24 million

Annual Gross Margin

81.86%
XERS annual gross profit margin is 81.86%

Annual Operating Profit

-$33.65 M
XERS annual operating income is -$33.65 million

Annual Operating Margin

-16.57%
XERS annual operating profit margin is -16.57%

Annual Net Income

-$54.84 M
XERS annual net profit is -$54.84 million

Annual Net Margin

-27.00%
XERS annual net profit margin is -27.00%

EPS

Annual EPS

-$0.37
XERS annual earnings per share is -$0.37

Annual EPS Analysts Estimate

-$0.30
XERS annual earnings per share is currently +23.33% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+17.78%
XERS annual earnings per share is up +17.78% year-on-year

Annual EPS Sector Rank

73.29%
XERS annual earnings per share is higher than 73.29% of companies in Healthcare sector

ROA & ROE

Annual ROA

-16.99%
XERS annual return on assets is -16.99%

Annual ROE

185.16%
XERS annual return on equity is 185.16%

EBIT & EBITDA

Annual EBIT

-$26.62 M
XERS annual earnings before interest & taxes is -$26.62 million

Annual EBITDA

-$13.99 M
XERS annual EBITDA is -$13.99 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
XERS price to earnings ratio value is unknown

PE Ratio Sector Rank

-
XERS price to earnings ratio is unknown

PB Ratio

PB Ratio

-21.68
XERS price to book ratio is -21.68

PB Ratio Sector Rank

1.73%
XERS price to book ratio is higher than 1.73% of companies in Healthcare sector

PS Ratio

PS Ratio

3.16
XERS price to sales ratio is 3.16

PS Ratio Sector Rank

50.2%
XERS price to sales ratio is higher than 50.2% of companies in Healthcare sector

Enterprise value

Enterprise Value

$842.02 M
XERS enterprise value is $842.02 million

Enterprise Value Sector Rank

72.7%
XERS enterprise value is higher than 72.7% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-60.17
XERS EV/EBITDA is -60.17

EV/EBITDA Sector Rank

2.19%
XERS EV/EBITDA is higher than 2.19% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

1.67
XERS annual current ratio is 1.67

Annual Quick Ratio

1.19
XERS annual quick ratio is 1.19

Leverage

Annual Debt To Equity

-7.84
XERS annual debt to equity ratio is -7.84

Annual Interest Coverage Ratio

-0.87
XERS annual interest coverage ratio is -0.87

Risk & Stability

Piotroski F-Score

4
XERS piotroski f-score is 4

Altman Z-Score

-1.21
XERS altman z-score is -1.21

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$323.06 M
XERS annual total assets is $323.06 million

Annual Non Current Assets

$155.40 M
XERS annual long term assets is $155.40 million

Annual Current Assets

$167.66 M
XERS annual total current assets is $167.66 million

Annual Cash & Cash Equivalents

$71.62 M
XERS annual cash & cash equivalents is $71.62 million

Equity

Annual Book Value

-$29.61 M
XERS annual book value is -$29.61 million

Annual Working Capital

$67.22 M
XERS annual working capital is $67.22 million

Liabilities

Annual Total Liabilities

$352.68 M
XERS annual total liabilities is $352.68 million

Annual Total Long Term Liabilities

$252.23 M
XERS annual total long term liabilities is $252.23 million

Annual Current Liabilities

$100.44 M
XERS annual total current liabilities is $100.44 million

Annual Accounts Payable

$2.29 M
XERS annual accounts payable is $2.29 million

Debt

Annual Total Debt

$271.45 M
XERS annual total debt is $271.45 million

Annual Total Debt 1-Year Change

+18.44%
XERS annual total debt is up +18.44% year-on-year

Annual Long Term Debt

$250.26 M
XERS annual long term debt is $250.26 million

Annual Short Term Debt

$21.18 M
XERS annual short term debt is $21.18 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$236.72 M
XERS annual total expenses is $236.72 million

Annual Operating Expenses

$199.88 M
XERS annual total operating expenses is $199.88 million

Annual Cost Of Goods Sold

$36.83 M
XERS annual cost of goods sold is $36.83 million

Annual SGA

$163.48 M
XERS annual SGA is $163.48 million

Annual D&A

$12.63 M
XERS annual depreciation & amortization is $12.63 million

Annual Interest Expense

$30.48 M
XERS annual interest expense is $30.48 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$36.98 M
XERS annual cash flow from operations is -$36.98 million

Annual CFO 1-Year Change

+21.36%
XERS annual cash flow from operations is up +21.36% year-on-year

Annual CFI

$4.88 M
XERS annual cash flow from investing activities is $4.88 million

Annual CFI 1-Year Change

+181.33%
XERS annual cash flow from investing activities is up +181.33% year-on-year

Annual CFF

$36.17 M
XERS annual cash flow from financing activities is $36.17 million

Annual CFF 1-Year Change

+2342.28%
XERS annual cash flow from financing activities is up +2342.28% year-on-year

Free CashFlow

Annual FCF

-$37.85 M
XERS annual free cash flow is -$37.85 million

Annual FCF 1-Year Change

+23.21%
XERS annual free cash flow is up +23.21% year-on-year

CAPEX

Annual CAPEX

$868.00 K
XERS annual capital expenditures is $868.00 thousand

Annual CAPEX 1-Year Change

-61.64%
XERS annual capital expenditures is down -61.64% year-on-year

Institutional Ownership

Similar stocks

ABUS logo
Arbutus Biopharma (ABUS)
TLRY logo
Tilray Brands (TLRY)
CRMD logo
CorMedix (CRMD)
LENZ logo
LENZ Therapeutics (LENZ)
KURA logo
Kura Oncology (KURA)
GHRS logo
GH Research (GHRS)
QURE logo
uniQure NV (QURE)
ORGO logo
Organogenesis Holdings (ORGO)
Beta Bionics (BBNX)

FAQ

  • What is the ticker symbol for Xeris Biopharma Holdings?
  • Does Xeris Biopharma Holdings pay dividends?
  • What sector is Xeris Biopharma Holdings in?
  • What industry is Xeris Biopharma Holdings in?
  • What country is Xeris Biopharma Holdings based in?
  • When did Xeris Biopharma Holdings go public?
  • Is Xeris Biopharma Holdings in the S&P 500?
  • Is Xeris Biopharma Holdings in the NASDAQ 100?
  • Is Xeris Biopharma Holdings in the Dow Jones?
  • When was Xeris Biopharma Holdings's last earnings report?
  • When does Xeris Biopharma Holdings report earnings?
  • Should I buy Xeris Biopharma Holdings stock now?

What is the ticker symbol for Xeris Biopharma Holdings?

The ticker symbol for Xeris Biopharma Holdings is NASDAQ:XERS

Does Xeris Biopharma Holdings pay dividends?

No, Xeris Biopharma Holdings does not pay dividends

What sector is Xeris Biopharma Holdings in?

Xeris Biopharma Holdings is in the Healthcare sector

What industry is Xeris Biopharma Holdings in?

Xeris Biopharma Holdings is in the Biotechnology industry

What country is Xeris Biopharma Holdings based in?

Xeris Biopharma Holdings is headquartered in United States

When did Xeris Biopharma Holdings go public?

Xeris Biopharma Holdings's initial public offering (IPO) was on June 21, 2018

Is Xeris Biopharma Holdings in the S&P 500?

No, Xeris Biopharma Holdings is not included in the S&P 500 index

Is Xeris Biopharma Holdings in the NASDAQ 100?

No, Xeris Biopharma Holdings is not included in the NASDAQ 100 index

Is Xeris Biopharma Holdings in the Dow Jones?

No, Xeris Biopharma Holdings is not included in the Dow Jones index

When was Xeris Biopharma Holdings's last earnings report?

Xeris Biopharma Holdings's most recent earnings report was on Mar 6, 2025

When does Xeris Biopharma Holdings report earnings?

The next expected earnings date for Xeris Biopharma Holdings is May 9, 2025

Should I buy Xeris Biopharma Holdings stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions